Eric Kauderer-Abrams
Coverage of Eric Kauderer-Abrams in the Nexus archive.
- AI giant Anthropic creates drug research tool, plans its own studies for overlooked diseases
Anthropic, an AI company, has developed a drug research tool called Claude Science to accelerate scientific discovery and is launching its own preclinical drug programs for neglected diseases. The company aims to address diseases less profitable for pharmaceutical industries by leveraging its public-benefit status to balance profit with public good.
- STAT+: AI company Anthropic announces it will begin developing drugs of its own
AI company Anthropic announced it will begin developing drugs, marking a new venture into life sciences. The company launched its newest application, Claude Science, and emphasized gaining hands-on experience to solve scientific problems using its AI products.
- Claude Science is Anthropic’s newest flagship product
Anthropic announced Claude Science, a new flagship product designed to support scientific research, particularly in computational biology and drug development. The product is now available to paid subscribers and will be used by Anthropic for its own research on rare diseases. The company positions it alongside Claude Code and Claude Cowork, emphasizing its commitment to AI-driven scientific advancements.